The most critical medical isotopes for diagnosing and treating cancer are produced in a handful of aging nuclear reactors, a supply chain that is as fragile as it is essential. StandardX, a London-based startup founded in 2025, is betting that the future of this supply, and eventually of fusion energy fuel, looks less like a sprawling nuclear campus and more like a standardized industrial machine. They are building what they call the world’s first scalable isotope refinery, a hardware platform that uses particle accelerators to manufacture rare isotopes from a compact footprint [StandardX, September 2026].
The refinery wedge
The company’s core bet is on reconfigurability. Today, producing different isotopes often requires bespoke, isotope-specific infrastructure, typically centered on large research reactors. StandardX’s proposed platform would use a single, standardized accelerator and target station design that can be reconfigured to produce a portfolio of isotopes [StandardX, September 2026]. The initial target is the medical market, where isotopes like lutetium-177 and actinium-225 are used in cutting-edge cancer therapies but face chronic supply shortages. By bringing production closer to end-users in a more flexible format, the company aims to address that fragility head-on [Indian Pharma Post, October 2026].
Why the check was written
In September 2026, StandardX announced a £10 million (approximately $13.35 million) seed round to move from concept to pilot. The round was co-led by Vsquared Ventures and East X Ventures, with participation from firstminute capital, UKI2S, Brevan Howard Macro Venture, and Geometry [StandardX, September 2026]. For climate and deeptech investors, the appeal is a two-stage market: a near-term, high-value medical application that can prove the technology, followed by a potential long-term play in fusion energy. The company has stated its platform could eventually produce tritium, a critical and scarce fuel for future fusion reactors [StandardX | Fusion, Unknown].
The capital is earmarked for developing the refinery platform and securing its first medical-isotope supply agreement, targeted for 2027 [Vestbee, September 2026]. Industrial-scale production is a longer-term goal, eyed for 2029. The 15-person team, assembled from organizations like SpaceX, Fermilab, and the UK Atomic Energy Authority, is now hiring for roles like Magnet Engineer and Lead Radiochemist to build it [Indian Pharma Post, October 2026] [StandardX Careers, retrieved 2026].
The team building a nuclear machine
The founders, Richard Pearson and Ross Allen, are both identified as nuclear engineers with startup scaling experience [StandardX, September 2026]. Public profiles suggest Pearson completed a PhD focused on fusion technology and policy, and was a co-founder of the fusion technology company Kyoto Fusioneering [ResearchGate, Unknown] [CERAWeek, Unknown]. Allen’s background includes robotics work at NASA’s Jet Propulsion Laboratory [Stanford Autonomous Systems Laboratory, Unknown]. This blend of deep technical nuclear expertise and hands-on hardware development from other frontier sectors is the team’s primary credential for a project of this complexity.
| Role | Name | Key Background Notes |
|---|---|---|
| Co-Founder & CEO | Richard Pearson | Nuclear engineer; PhD in fusion technology & policy; co-founder of Kyoto Fusioneering [StandardX, September 2026] [ResearchGate, Unknown]. |
| Co-Founder & CTO | Ross Allen | Nuclear engineer; roboticist at NASA JPL; background in aerospace engineering [StandardX, September 2026] [Stanford Autonomous Systems Laboratory, Unknown]. |
The scale of the ambition
StandardX’s roadmap requires navigating two of the most stringent regulatory and technical environments imaginable: medical radiopharmaceuticals and nuclear fusion. The risks are not subtle, but they are specific.
- Technical integration. The promise of a single, reconfigurable platform producing pharmaceutical-grade isotopes is a profound engineering challenge. Each new isotope target will require fresh validation under Good Manufacturing Practice (GMP) standards, a process that is neither cheap nor fast.
- Market timing. The fusion energy application is a classic venture moonshot, dependent on the success of an entire industry that is still in its experimental phase. The medical isotope business must achieve commercial scale and profitability to fund that long runway.
- Capital intensity. £10 million is a substantial seed, but it is a down payment for a hardware company building particle accelerators. Subsequent rounds will need to be significantly larger to reach the 2029 industrial production target, demanding relentless execution to hit the milestones that justify them.
The company’s answer to these risks is its wedge: start with the high-value, urgent needs of oncology, where supply constraints create clear pricing power and customer demand. Prove the machine works and can be certified there first.
The unit economics of an isotope
While detailed pricing is not public, the value of securing supply is easy to illustrate. A single dose of a targeted alpha therapy using actinium-225 can cost tens of thousands of dollars. The global market for medical radioisotopes was valued at over $10 billion in 2023, with growth driven by precision oncology [Grand View Research, 2023]. If StandardX’s platform can reliably produce even a small fraction of the isotopes in that market, the revenue per machine starts to make the capital expenditure look manageable. The back-of-the-envelope math is simple: higher utilization of a single, flexible asset beats the economics of dedicated, single-purpose plants.
For StandardX to succeed, its reconfigurable refinery must eventually outperform the incumbent it seeks to complement and disrupt: the global network of multipurpose research reactors like Belgium’s BR2 or Canada’s NRU, which currently produce many of these isotopes. It doesn’t need to replace them overnight. It just needs to prove that for the next generation of isotope demand, a standardized, accelerator-based machine is a more scalable and reliable answer. That is a bet worth £10 million, and several years of very hard engineering.
Sources
- [StandardX, September 2026] StandardX launches with £10m seed round to create the rare isotopes needed to advance medical and fusion innovation | https://www.standardx.tech/news-stories/standardx-launches-with-ps10m-seed-round-to-create-the-rare-isotopes-needed-to-advance-medical-and-fusion-innovation
- [Tech.eu, September 2026] StandardX launches with £10M to expand isotope production for medicine and fusion | https://tech.eu/2026/09/23/standardx-launches-with-ps10m-to-expand-isotope-production-for-medicine-and-fusion/
- [Indian Pharma Post, October 2026] StandardX raises 10m to build isotope refinery for cancer care and fusion | https://www.indianpharmapost.com/startup/standardx-raises-10m-to-build-isotope-refinery-for-cancer-care-and-fusion-21964
- [Vestbee, September 2026] StandardX lands £10M to develop scalable isotope … | https://www.vestbee.com/insights/articles/standard-x-lands-10-m
- [StandardX | Fusion, Unknown] StandardX is developing a reliable external source of tritium | https://www.standardx.tech/fusion
- [StandardX Careers, retrieved 2026] StandardX Careers page | https://careers.standardx.tech/jobs
- [ResearchGate, Unknown] Richard Pearson PhD research profile | https://www.researchgate.net/profile/Richard-Pearson-97
- [CERAWeek, Unknown] Richard Pearson biography | https://www.ceraweek.com/speakers/richard-pearson
- [Stanford Autonomous Systems Laboratory, Unknown] Ross Allen background | https://asl.stanford.edu/people/ross-allen
- [Grand View Research, 2023] Medical Radioisotopes Market Size Report | https://www.grandviewresearch.com/industry-analysis/medical-radioisotopes-market